World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
104
Citations
46628
World Ranking
6980
National Ranking
683

David C. Linch publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where David C. Linch sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 674 publications — 79th percentile

79% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

David C. Linch D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where David C. Linch sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 104 D-Index — 66th percentile

66% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

David C. Linch is affiliated with University College London in the United Kingdom. Their research primarily spans the field of Medicine, focusing on various subfields such as Oncology, Hematology, Molecular Biology, Genetics, and Pathology and Forensic Medicine.

The scientist's work covers a range of topics, including:

  • Acute Myeloid Leukemia Research
  • CAR-T cell therapy research
  • Lymphoma Diagnosis and Treatment
  • Acute Lymphoblastic Leukemia research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Viral-associated cancers and disorders
  • Immune Cell Function and Interaction

David C. Linch has authored and co-authored numerous papers, with recent notable publications including:

  • Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study, 2020, BMJ Open
  • Estimating excess mortality in people with cancer and multimorbidity in the COVID-19 emergency, 2020, bioRxiv (Cold Spring Harbor Laboratory)
  • Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, 2021, Journal of Clinical Oncology
  • Dual targeting of CD19 and CD22 with Bicistronic CAR-T cells in Patients with Relapsed/Refractory Large B Cell Lymphoma, 2023, Blood
  • EZH2-Deficient T-cell Acute Lymphoblastic Leukemia Is Sensitized to CHK1 Inhibition through Enhanced Replication Stress, 2020, Cancer Discovery

Frequent collaborators include Rosemary E. Gale, Robert K. Hills, Martin Pulé, Claire Roddie, and Karl S. Peggs. These coauthors have worked together in various capacities on multiple studies and publications.

The venues where David C. Linch frequently publishes reflect their research focus, including:

  • Blood
  • British Journal of Haematology
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Nature Communications
  • Hematological Oncology

Best Publications

  • The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.

    Panagiotis D. Kottaridis;Rosemary E. Gale;Marion E. Frew;Georgina Harrison

  • Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B

    Amit C. Nathwani;Edward G.D. Tuddenham;Savita Rangarajan;Cecilia Rosales

  • Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

    Christian Gisselbrecht;Bertram Glass;Nicolas Mounier;Devinder Singh Gill

  • Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients

    Steven J. Howe;Marc R. Mansour;Kerstin Schwarzwaelder;Cynthia Bartholomae

  • Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

    D C Linch;D Winfield;A H Goldstone;D Moir

  • The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia

    Rosemary E. Gale;Claire Green;Christopher Allen;Adam J. Mead

  • Assessment of Minimal Residual Disease in Standard-Risk AML.

    Adam Ivey;Robert Kerrin Hills;Michael A. Simpson;Jelena V. Jovanovic

  • Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients

    N Schmitz;P Dreger;D.C Linch;A.H Goldstone

  • Risk of Second Malignancy After Hodgkin’s Disease in a Collaborative British Cohort: The Relation to Age at Treatment

    A J Swerdlow;J A Barber;G V Hudson;D Cunningham

  • Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial.

    KM Ardeshna;P Smith;A Norton;BW Hancock

  • Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

    David Cunningham;Eliza A Hawkes;Andrew Jack;Wendi Qian

  • In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.

    Panagiotis D Kottaridis;Donald W Milligan;Rajesh Chopra;Ronjon Chakraverty

  • Acute myeloid leukaemia.

    Asim Khwaja;Magnus Bjorkholm;Rosemary E Gale;Ross L Levine

  • A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells

    James D. Griffin;David Linch;Kert Sabbath;Peter Larcom

  • Myocardial Infarction Mortality Risk After Treatment for Hodgkin Disease: A Collaborative British Cohort Study

    Anthony J. Swerdlow;Craig D. Higgins;Paul Smith;David Cunningham

  • Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study.

    ME Hill;KA MacLennan;DC Cunningham;B Vaughan Hudson

  • High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution.

    Suparno Chakrabarti;Stephen Mackinnon;Rajesh Chopra;Panagiotis D Kottaridis

  • Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial

    Kirit M Ardeshna;Wendi Qian;Paul Smith;Nivette Braganca

  • Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors

    Panagiotis D. Kottaridis;Rosemary E. Gale;Rosemary E. Gale;Stephen E. Langabeer;Stephen E. Langabeer;Marion E. Frew;Marion E. Frew

  • FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia.

    Adam J. Mead;David C. Linch;Robert Kerrin Hills;Keith Wheatley

Frequent Co-Authors

Anthony H. Goldstone
Anthony H. Goldstone University College Hospital
Alan Kenneth Burnett
Alan Kenneth Burnett University of Glasgow
Robert Kerrin Hills
Robert Kerrin Hills University of Oxford
Karl S. Peggs
Karl S. Peggs University College London
Emma Morris
Emma Morris University College London
David Cunningham
David Cunningham Royal Marsden NHS Foundation Trust
Donald Milligan
Donald Milligan University of Birmingham
Peter Hoskin
Peter Hoskin University of Manchester
John Radford
John Radford University of Manchester
Claire N. Harrison
Claire N. Harrison Guy's and St Thomas' NHS Foundation Trust

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Medicine is a diverse field with many rewarding career routes beyond becoming a physician. For those interested in blending healthcare and nutrition, earning a nutrition bachelor degree online can open doors to roles in dietetics and wellness coaching. Programs in this area focus on the science of food, human biology, and promoting healthier lifestyles.

If you aspire to enter healthcare leadership, pursuing one of the top cahme-accredited mha programs is a strategic move. Accredited online MHA degrees provide critical skills in management, operations, and policy, helping graduates advance into hospital administration and executive roles.

Nursing is another expanding area with flexible online education options. Many registered nurses accelerate their careers by enrolling in rn to bsn programs without clinicals, which allow them to earn a Bachelor of Science in Nursing entirely online without additional hands-on clinical requirements.

For nurses aiming for the highest clinical or leadership positions, dnp online programs offer flexible pathways to a Doctor of Nursing Practice. These online degrees are designed for working professionals seeking to enhance their expertise and make a greater impact in patient outcomes or healthcare systems.

Best Scientists Citing David C. Linch

Trending Scientists

Recently Published Articles